Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

Diagnosis of ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer

Stage III or IV disease
HLA-A1, -A2, and/or -A3 positive
Must have at least 1 undissected axillary or inguinal lymph node basin
No recurrent disease

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Hemoglobin ≥ 8.0 g/dL
WBC > 3,000/mm^3
Absolute neutrophil count > 1,500/mm^3
Hemoglobin A1c < 7%
AST and ALT ≤ 2.5 times upper limit of normal (ULN)
Bilirubin ≤ 2.5 times ULN
Creatinine ≤ 1.5 times ULN
HIV negative
Hepatitis C negative
No known or suspected allergies to any component of the study vaccine
No other concurrent malignancy (except for nonmelanoma skin cancer) unless the patient was curatively treated and has been disease free for ≥ 5 years
No active serious infection
No autoimmune disorder with visceral involvement

No prior or active autoimmune disorders requiring cytotoxic or immunosuppressive therapy

The following immunologic conditions are allowed:

Laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer) without symptoms
Clinical evidence of vitiligo
Other forms of depigmenting illness
Mild arthritis requiring NSAIDs
No New York Heart Association class III or IV heart disease
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No medical contraindication or potential problem that would preclude study compliance

PRIOR CONCURRENT THERAPY:

At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal antibodies)
More than 4 weeks since prior and no other concurrent investigational agents
More than 4 weeks since prior and no concurrent allergy desensitization injections
More than 4 weeks since prior and no concurrent oral or parenteral systemic corticosteroids

No prior or concurrent inhaled corticosteroids (e.g., fluticasone and salmetrol, fluticasone, or triamcinolone acetonide)

Prior or concurrent topical corticosteroids allowed
No prior vaccination with MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-104, or Her-2/neu:754-762
More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)
No concurrent treatment for recurrent disease
No concurrent nitrosoureas
No concurrent illegal drug use
Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, and chronic medications, unless excluded, are allowed
Short-term therapy for acute conditions not specifically related to ovarian cancer is allowed